1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chronic Back Pain - Pipeline Review, H1 2014

Chronic Back Pain - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 64 pages

Chronic Back Pain - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Chronic Back Pain - Pipeline Review, H1 2014’, provides an overview of the Chronic Back Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Back Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Back Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Back Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Back Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Chronic Back Pain - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Back Pain Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Back Pain - Overview 8
Pipeline Products for Chronic Back Pain - Comparative Analysis 9
Chronic Back Pain - Therapeutics under Development by Companies 10
Chronic Back Pain - Therapeutics under Investigation by Universities/Institutes 12
Chronic Back Pain - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Chronic Back Pain - Products under Development by Companies 16
Chronic Back Pain - Products under Investigation by Universities/Institutes 17
Chronic Back Pain - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Pfizer Inc. 19
Teva Pharmaceutical Industries Limited 20
Collegium Pharmaceutical, Inc. 21
Grunenthal GmbH 22
Endo Pharmaceuticals Inc. 23
Adynxx, Inc. 24
Akron Molecules GmbH 25
Chronic Back Pain - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
hydrocodone bitartrate ER - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
buprenorphine hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
cycloserine - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
oxycodone ER - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
(oxycodone hydrochloride + naltrexone hydrochloride) Extended Release - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
cebranopadol - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
AKR-202 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
AKR-203 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
ASP-7962 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
AYX-2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Chronic Back Pain - Recent Pipeline Updates 50
Chronic Back Pain - Dormant Projects 58
Chronic Back Pain - Discontinued Products 59
Chronic Back Pain - Product Development Milestones 60
Featured News and Press Releases 60
Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program 60
Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 61
Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 61
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 62
Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables

Number of Products under Development for Chronic Back Pain, H1 2014 8
Number of Products under Development for Chronic Back Pain - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Chronic Back Pain - Pipeline by Astellas Pharma Inc., H1 2014 18
Chronic Back Pain - Pipeline by Pfizer Inc., H1 2014 19
Chronic Back Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 20
Chronic Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H1 2014 21
Chronic Back Pain - Pipeline by Grunenthal GmbH, H1 2014 22
Chronic Back Pain - Pipeline by Endo Pharmaceuticals Inc., H1 2014 23
Chronic Back Pain - Pipeline by Adynxx, Inc., H1 2014 24
Chronic Back Pain - Pipeline by Akron Molecules GmbH, H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Assessment by Combination Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Chronic Back Pain Therapeutics - Recent Pipeline Updates, H1 2014 50
Chronic Back Pain - Dormant Projects, H1 2014 58
Chronic Back Pain - Discontinued Products, H1 2014 59

List of Figures

Number of Products under Development for Chronic Back Pain, H1 2014 8
Number of Products under Development for Chronic Back Pain - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, ...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

  • $ 3080
  • Industry report
  • September 2016
  • by MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing ...

Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2016 Market Research Report

Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global N, N-dieth ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Related Market Segments :

Opioid
Musculoskeletal Disorder
Pharmaceutical

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.